Skip to content
value.today

BridgeBio Oncology Therapeutics, Inc.

BBOT
$217 Mmarket cap on Oct 30, 2026
Compare
World rank
#15,960
Revenue
—
For year ending December-2025
Net income
$-134 M
SEC filing
Employees
92
As of December 31, 2025
SEC filing

BridgeBio Oncology Therapeutics, Inc. in brief

BridgeBio Oncology Therapeutics, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $217 M on 30 October 2026, which makes it the 15,960th largest listed company in the world and the 3,106th largest in the USA on this site. It employs about 92 people. Its shares trade under the symbol BBOT (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About BridgeBio Oncology Therapeutics, Inc.

BBOT is a clinical-stage biotechnology company with the mission of transforming the lives of patients with cancers driven by RAS and PI3Kα, the two most frequently mutated oncogenes. Aberrant RAS signaling drives uncontrolled tumor growth in some of the deadliest cancers, including lung, breast, pancreas and colon cancer. This can come from mutations in RAS itself, which underlie approximately 30% of all human cancers, or from RAS-mediated overactivation of PI3Kα. Our goal is to provide meaningful benefit to patients by designing and developing new therapies to achieve high levels of target inhibition against these oncogenic drivers while maintaining a favorable tolerability profile.

From the company's annual report filed with the US SEC: read the report

BridgeBio Oncology Therapeutics, Inc. timeline

3 events, 2023–2025
  1. 2023
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2024
  4. 🔔
    Initial public offering as Helix Acquisition Corp. II
    Final prospectus filed with the SEC on 13 February 2024; shares registered for exchange trading on 8 February 2024. The blank-check company later merged with the business that carries the name today.
  5. 2025
  6. ✎
    Renamed BridgeBio Oncology Therapeutics, Inc.
    Formerly Helix Acquisition Corp. II.

Events of BridgeBio Oncology Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

Not enough history yet.

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.5×
Free cash flow yield
-52.8%
Net margin
—
Operating margin
—
Return on equity
-32.6%
Liabilities / assets
8.3%
Profit per employee
$-1.5 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2023: revenue —, net income $-0M—FY23Fiscal year ending Dec 2024: revenue —, net income $-74M—FY24Fiscal year ending Dec 2025: revenue —, net income $-134M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-146M$-134M—
Dec 2024——$-81M$-74M—
Dec 2023——$-0M$-0M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-114M$1M$-115M$-4.30—
Dec 2024$-55M$0M$-55M$-5756.41—
Dec 2023—————

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024: revenue —, net income $-20M—Dec ’24Three months to Mar 2025: revenue —, net income $-22M—Mar ’25Three months to Jun 2025: revenue —, net income $-28M—Jun ’25Three months to Sep 2025: revenue —, net income $-45M—Sep ’25Three months to Dec 2025: revenue —, net income $-39M—Dec ’25Three months to Mar 2026: revenue —, net income $-42M—Mar ’26Three months to Jun 2026: revenue —, net income $-56M—Jun ’26Three months to Sep 2026: revenue —, net income $-34M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-34M. Trailing 12 months to Sep 2026.

SEC filings

Official filings of BridgeBio Oncology Therapeutics, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-146 M
Net income
$-134 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$448 M
Total liabilities
$37 M
Total equity
$411 M

As of December-2025

Top 89 institutional investors in BridgeBio Oncology Therapeutics, Inc.#

As of Sep 30, 2026
89 institutions held 60.3 M shares (about 75.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 54.2%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in BridgeBio Oncology Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Cormorant Asset Management, LP17,878,5940 (0.00%)22.28%$73 MNov 16, 2026
2BlackRock, Inc.4,009,791+1,855,751 (+86.15%)5.00%$16 MNov 13, 2026
3Omega Fund Management, LLC3,289,6610 (0.00%)4.10%$13 MNov 16, 2026
4Deerfield Management Company, L.P.3,138,167-1,747,279 (-35.76%)3.91%$13 MNov 16, 2026
5Alphabet Inc.2,823,1260 (0.00%)3.52%$12 MNov 6, 2026
6Citadel Advisors LLC2,697,077+79,250 (+3.03%)3.36%$11 MNov 16, 2026
7Enavate Sciences GP, LLC2,626,9460 (0.00%)3.27%$11 MNov 16, 2026
8Regents Of The University Of California2,509,446New3.13%$10 MOct 26, 2026
9Armistice Capital, LLC2,264,000+500,000 (+28.34%)2.82%$9 MNov 16, 2026
10Novo Holdings A/s2,250,0000 (0.00%)2.80%$9 MNov 16, 2026
11Laurion Capital Management LP2,002,7010 (0.00%)2.50%$8 MOct 30, 2026
12Vanguard Capital Management LLC1,991,016-14,633 (-0.73%)2.48%$8 MNov 13, 2026
13Wellington Management Group LLP1,430,687-1,358,615 (-48.71%)1.78%$6 MNov 16, 2026
14Aisling Capital Management LP1,018,0180 (0.00%)1.27%$4 MNov 12, 2026
15State Street Corp893,262-143,307 (-13.83%)1.11%$4 MNov 12, 2026
16EcoR1 Capital, LLC889,607-1,933,519 (-68.49%)1.11%$4 MNov 16, 2026
17Catalio Capital Management, LP699,532+381,125 (+119.70%)0.87%$3 MNov 16, 2026
18Opaleye Management Inc.630,000-70,000 (-10.00%)0.79%$3 MNov 16, 2026
19Geode Capital Management, LLC556,989-65,362 (-10.50%)0.69%$2 MNov 6, 2026
20Marshall Wace, LLP482,935New0.60%$2 MNov 13, 2026
21Sphera Funds Management LTD.464,480+3,495 (+0.76%)0.58%$2 MNov 16, 2026
22Granahan Investment Management, LLC437,004-121,522 (-21.76%)0.54%$2 MNov 16, 2026
23Adage Capital Partners GP, L.L.C.400,0000 (0.00%)0.50%$2 MNov 16, 2026
24BNP Paribas Financial Markets349,576+158,424 (+82.88%)0.44%$1 MNov 12, 2026
25Price T Rowe Associates Inc /MD/298,798-1,202 (-0.40%)0.37%$1 MNov 16, 2026
Show all 89: investors 26 to 89
Institutional investors 26 to 89 in BridgeBio Oncology Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Qube Research & Technologies Ltd290,548New0.36%$1 MNov 13, 2026
27Charles Schwab Investment Management Inc285,709-809 (-0.28%)0.36%$1 MNov 16, 2026
28Casdin Capital, LLC282,3120 (0.00%)0.35%$1 MNov 16, 2026
29DAFNA Capital Management LLC266,038New0.33%$1 MNov 16, 2026
30Vanguard Fiduciary Trust Co264,427-27,095 (-9.29%)0.33%$1 MNov 13, 2026
31Goldman Sachs Group Inc239,614+137,529 (+134.72%)0.30%$1 MNov 16, 2026
32Ensign Peak Advisors, Inc228,620-44,910 (-16.42%)0.28%$1 MNov 12, 2026
33Brevan Howard Capital Management LP165,133+76,238 (+85.76%)0.21%$1 MNov 16, 2026
34Squarepoint Ops LLC156,980+137,318 (+698.39%)0.20%$1 MNov 9, 2026
35Millennium Management LLC144,430+38,950 (+36.93%)0.18%$1 MNov 16, 2026
36Victory Capital Management Inc128,563New0.16%$1 MNov 10, 2026
37Moore Capital Management, LP100,0000 (0.00%)0.12%$0 MNov 16, 2026
38Tidal Investments LLC99,750+6,411 (+6.87%)0.12%$0 MNov 13, 2026
39Tema Etfs LLC99,750+6,411 (+6.87%)0.12%$0 MOct 16, 2026
40Palumbo Wealth Management LLC95,443+9,819 (+11.47%)0.12%$0 MNov 13, 2026
41Royal Bank Of Canada82,439New0.10%$0 MNov 16, 2026
42Schonfeld Strategic Advisors LLC67,861+56,357 (+489.89%)0.08%$0 MNov 16, 2026
43Renaissance Technologies LLC64,000+5,400 (+9.22%)0.08%$0 MNov 12, 2026
44ExodusPoint Capital Management, LP60,597New0.08%$0 MNov 16, 2026
45EntryPoint Capital, LLC54,756New0.07%$0 MNov 13, 2026
46Axq Capital, LP53,001+42,273 (+394.04%)0.07%$0 MNov 12, 2026
47Dimensional Fund Advisors LP52,406New0.07%$0 MNov 4, 2026
48Bank Of America Corp /de/50,816-26,324 (-34.12%)0.06%$0 MNov 16, 2026
49Fox Run Management, L.L.C.50,778New0.06%$0 MNov 12, 2026
50Susquehanna Portfolio Strategies, LLC48,230New0.06%$0 MNov 16, 2026
51TD Asset Management Inc42,7300 (0.00%)0.05%$0 MNov 13, 2026
52Virtus Investment Advisers, LLC40,946-1,274 (-3.02%)0.05%$0 MNov 12, 2026
53Morgan Stanley38,899+35,519 (+1050.86%)0.05%$0 MNov 13, 2026
54Y-Intercept (Hong Kong) Ltd38,846New0.05%$0 MOct 16, 2026
55Canada Pension Plan Investment Board38,300New0.05%$0 MNov 16, 2026
56XTX Topco Ltd37,065New0.05%$0 MNov 16, 2026
57Ameriprise Financial Inc35,907New0.04%$0 MNov 16, 2026
58UBS Group AG31,825-82,830 (-72.24%)0.04%$0 MNov 10, 2026
59Catalyst Funds Management Pty Ltd30,601New0.04%$0 MNov 12, 2026
60Mercer Global Advisors Inc /adv30,000New0.04%$0 MNov 16, 2026
61Point72 Asset Management, L.P.29,570New0.04%$0 MNov 16, 2026
62Rafferty Asset Management, LLC28,581+5,975 (+26.43%)0.04%$0 MNov 13, 2026
63Manufacturers Life Insurance Company, The28,016+32 (+0.11%)0.03%$0 MNov 13, 2026
64Jump Financial, LLC26,775-35,225 (-56.81%)0.03%$0 MNov 13, 2026
65Trexquant Investment LP26,360New0.03%$0 MNov 16, 2026
66Northern Trust Corp25,000-161,482 (-86.59%)0.03%$0 MNov 16, 2026
67CIBC Bancorp USA Inc.25,000New0.03%$0 MNov 13, 2026
68FMR LLC24,479-216,108 (-89.83%)0.03%$0 MNov 10, 2026
69Aster Capital Management (DIFC) Ltd21,220New0.03%$0 MNov 12, 2026
70Virtu Financial LLC20,926New0.03%$0 MNov 17, 2026
71PDT Partners, LLC20,801New0.03%$0 MNov 16, 2026
72Barclays PLC19,924+17,825 (+849.21%)0.02%$0 MNov 6, 2026
73Jain Global LLC18,535New0.02%$0 MNov 16, 2026
74Vanguard Global Advisers, LLC18,1630 (0.00%)0.02%$0 MNov 13, 2026
75ADAR1 Capital Management, LLC17,183New0.02%$0 MNov 16, 2026
76Gsa Capital Partners LLP16,608New0.02%$0 MNov 16, 2026
77China Universal Asset Management Co., Ltd.16,000New0.02%$0 MOct 28, 2026
78Hudson Bay Capital Management LP13,742New0.02%$0 MNov 13, 2026
79Prelude Capital Management, LLC13,124New0.02%$0 MNov 16, 2026
80HSBC Holdings PLC12,259New0.02%$0 MNov 16, 2026
81Citigroup Inc10,875-8,997 (-45.27%)0.01%$0 MNov 4, 2026
82Tower Research Capital LLC (TRC)4,367+2,671 (+157.49%)0.01%$0 MNov 16, 2026
83MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.2,212-414 (-15.77%)0.00%$0 MNov 16, 2026
84Rockefeller Capital Management L.P.2,000+1,000 (+100.00%)0.00%$0 MNov 13, 2026
85Quarry LP1,696+1,499 (+760.91%)0.00%$0 MNov 16, 2026
86Toth Financial Advisory Corp1,600New0.00%$0 MOct 8, 2026
87Nuveen, LLC960New0.00%$0 MNov 10, 2026
88Wells Fargo & Company/mn3000 (0.00%)0.00%$0 MNov 16, 2026
89SBI Securities Co., Ltd.187New0.00%$0 MOct 22, 2026

Mutual funds holding BridgeBio Oncology Therapeutics, Inc.#

39 funds hold shares worth $49 M (about 7.7% of the company). Since their previous reports 19 added shares and 10 sold, buying $16 M net.
Mutual funds holding BridgeBio Oncology Therapeutics, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.42 M$11 M1.8%<0.01%newJun 30, 2026
🇺🇸 State Street SPDR S&P Biotech ETFSSGA Funds Management, Inc.813,301$6 M1.0%0.06%newJun 30, 2026
🇺🇸 BlackRock Health Sciences Opportunities PortfolioBlackRock Advisors, LLC673,766$6 M0.84%0.10%no changeMay 29, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.539,581$4 M0.67%<0.01%+0.3%Jun 30, 2026
🇺🇸 iShares Biotechnology ETFBlackRock Fund Advisors306,024$2 M0.38%0.03%−5.7%Jun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC250,892$2 M0.31%<0.01%−0.7%May 31, 2026
🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC240,300$2 M0.30%0.04%no changeMay 31, 2026
🇺🇸 Schwab U.S. Small-Cap ETFCharles Schwab Investment Management, Inc.227,258$2 M0.28%<0.01%−1.5%May 31, 2026
🇺🇸 BlackRock Health Sciences Term TrustBlackRock Advisors, LLC263,669$2 M0.33%0.19%no changeJun 30, 2026
🇺🇸 T. Rowe Price Health Sciences Fund, Inc.T. Rowe Price Associates, Inc.222,512$2 M0.28%0.01%−33%Jun 30, 2026
🇺🇸 Royce Micro-Cap Trust, Inc.Royce & Associates, LP210,854$2 M0.26%0.18%+42%Jun 30, 2026
🇺🇸 Victory Small Cap Stock FundVictory Capital Management Inc.134,743$1 M0.17%0.11%+62%Jul 31, 2026
🇺🇸 Tema Oncology ETFTema ETFs LLC93,339$1 M0.12%0.48%newMay 31, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC90,376$1 M0.11%<0.01%no changeMay 31, 2026
🇺🇸 Royce Micro-Cap FundRoyce & Associates, LP87,617$1 M0.11%0.16%+27%Jun 30, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC72,932$1 M0.09%<0.01%+4.8%May 31, 2026
🇺🇸 BlackRock Health Sciences TrustBlackRock Advisors, LLC60,030$0 M0.07%0.08%no changeJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC49,459$0 M0.06%<0.01%+2.3%May 31, 2026
🇺🇸 Royce Small-Cap Trust, Inc.Royce & Associates, LP44,789$0 M0.06%0.01%−79%Jun 30, 2026
🇺🇸 Health Sciences PortfolioPacific Life Fund Advisors LLC40,663$0 M0.05%0.08%no changeJun 30, 2026
🇺🇸 Royce Small-Cap FundRoyce & Associates, LP38,053$0 M0.05%0.01%−79%Jun 30, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.32,000$0 M0.04%<0.01%no changeJul 31, 2026
🇺🇸 Schwab U.S. Broad Market ETFCharles Schwab Investment Management, Inc.27,500$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Direxion Daily S&P Biotech Bull 3X SharesRAFFERTY ASSET MANAGEMENT, LLC27,634$0 M0.03%0.05%newJul 31, 2026
🇺🇸 Royce Capital Fund - Micro-Cap PortfolioRoyce & Associates, LP28,976$0 M0.04%0.16%—Jun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.28,792$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC24,941$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC24,350$0 M0.03%0.16%—Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC18,529$0 M0.02%<0.01%+11%Jul 31, 2026
🇺🇸 T. Rowe Price Health Sciences PortfolioT. Rowe Price Associates, Inc.15,774$0 M0.02%0.02%−26%Jun 30, 2026
🇺🇸 Small Cap Core FundNorthern Trust Investments, Inc.15,579$0 M0.02%0.03%newJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC7,506$0 M<0.01%0.01%+3.6%Jul 31, 2026
🇺🇸 Health Sciences TrustJohn Hancock Variable Trust Advisers LLC7,262$0 M<0.01%0.02%−26%Jun 30, 2026
🇺🇸 EQ/T.Rowe Price Health Sciences PortfolioEquitable Investment Management Group, LLC4,884$0 M<0.01%0.02%−26%Jun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.4,825$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC4,161$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.3,155$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC1,414$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC1,180$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 39 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at BridgeBio Oncology Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$185
1 sale, 1 insider
Net, 12 months
-$185
open market only
Insiders on file
11
since
$24.0 M-$185$0Feb 2024: bought $24.0 M (3 trades), sold $0 (0 trades)Feb 24Nov 2026: bought $0 (0 trades), sold $185 (1 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
BridgeBio Oncology Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Marc CoboPrincipal Accounting OfficerSell10b5-1 plan-78$2.370$18513,734Form 4
filed Marc CoboPrincipal Accounting OfficerShares withheld for tax-203$2.680$54413,812Form 4
filed Pedro BeltranPresident and CEO, DirectorShares withheld for tax-1,047$3.940$4 K43,529Form 4
filed Marc CoboPrincipal Accounting OfficerShares withheld for tax-126$3.940$49614,015Form 4
filed Idan ElmelechCOO & Principal Financial OfcrShares withheld for tax-343$3.940$1 K14,152Form 4
filed Yong BenChief Med & Dev OfficerShares withheld for tax-1,047$3.940$4 K43,529Form 4
filed Marc CoboPrincipal Accounting OfficerGrant or award+9,038——14,344Form 4
filed Marc CoboPrincipal Accounting OfficerShares withheld for tax-203$5.520$1 K14,141Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: BridgeBio Oncology Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
3.5 M
5.1 days to cover
Shares sold short, last 24 reportsAll stocks →

Fails to deliver

  • : 4,420 shares at $2.70
  • : 1 shares at $10.23
  • : 171,200 shares at $2.72
  • : 105,672 shares at $10.32
  • : 2,988 shares at $3.94

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

BridgeBio Oncology Therapeutics, Inc. scorecard#

Passes 2 of the 8 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation1 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-52.8%Free cash flow is -52.8% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 1
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-4.30 vs -5756.41Diluted EPS -4.30 in fiscal 2025 against -5756.41 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$134 MNet income -$134 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-115.3%-115.3% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities12.3×Current ratio 12.34 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

BridgeBio Oncology Therapeutics, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

BridgeBio Oncology Therapeutics, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023
Income statement
Research and development12173—
General and administrative257.8r0.0
Operating expenses14681—
Operating income−146−81r−0.0
Interest and finance income—8.4—
Other non-operating income (expense)126.6r—
Income tax00—
Net income attributable to shareholders−134−74r−0.0
Earnings per share, basic-4.30-5,756.41—
Earnings per share, diluted-4.30-5,756.41—
Shares, weighted average (basic)310.0—
Shares, weighted average (diluted)310.0—
Balance sheet
Cash and cash equivalents374310
Short-term investments52125—
Other current assets6.63.0r—
Current assets432159r—
Property, plant and equipment1.00.5—
Right-of-use (leased) assets2.30—
Total assets448164r0.3
Accounts payable1.43.1r—
Current liabilities3520r0.4
Lease liabilities (non-current)2.20—
Total liabilities3720r0.4
Retained earnings−357−223r−0.1
Shareholders' equity411−179r−116r
Total liabilities and equity448164r0.3
Shares outstanding800.0—
Cash-flow statement
Share-based compensation5.94.4r—
Cash from operating activities−114−55r—
Capital expenditure−0.6−0.0—
Cash from investing activities73−121r—
Shares issued112——
Cash from financing activities383206r—
Report10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Events at BridgeBio Oncology Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Auditor changedFiling

Auditor changed 1 · Change in control 1 · Acquisition or sale completed 1 · Directors and officers 8 · Material agreement 3 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 5

BridgeBio Oncology Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Results announced8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Auditor changedChange in controlAcquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

How BridgeBio Oncology Therapeutics, Inc. compares in Biotechnology

  • Market cap$217 M · higher than 45% of 726
  • Price / book0.5× · lower than 91% of 534
  • FCF yield-52.8% · higher than 23% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
BridgeBio Oncology Therapeutics, Inc.🇺🇸$217 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BridgeBio Oncology Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BridgeBio Oncology Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BridgeBio Oncology Therapeutics, Inc.? Suggest a correction